|
Ortiz-Fernandez P, Iniesta-Navalon C, Urbieta-Sanz E, Gascon-Canovas JJ. Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: "early therapeutic drug monitoring of adalimumab". Clin Rheumatol. 2025 Jan 18. doi: 10.1007/s10067-025-07307-0. Online ahead of print. PubMed PMID: 39826047.
AÑO: 2025; IF: 2.9
|
|
Iniesta-Navalon C, Rentero-Redondo L, Gomez-Espin R, Rios Saorin M, Nicolas de Prado I, Gascon-Canovas JJ. Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes. Gastroenterol Hepatol. 2025 May 23:502472. doi: 10.1016/j.gastrohep.2025.502472. Online ahead of print. English, Spanish. PubMed PMID: 40414284.
AÑO: 2025; IF: 2.2
|
|
Iniesta-Navalon C, Saorin MR, Neira-Torrecillas JM, Rentero-Redondo L, Garcia-Masegosa I, Gil-Almela J, Urbieta-Sanz E. External Evaluation of Population Pharmacokinetic Models of Ustekinumab in Patients with Inflammatory Bowel Disease. Ther Drug Monit. 2025 Apr 3. doi: 10.1097/FTD.0000000000001329. Online ahead of print. PubMed PMID: 40178486.
AÑO: 2025; IF: 2.8
|
|
Solana-Altabella A, Iniesta-Navalon C, Chovi-Trull M, Rodriguez-Veiga R, Lopez-Nogueroles M, Martinez-Cuadron D, Gil-Candel M, Torres-Minana L, Acuna-Cruz E, Cano-Ferri I, Boluda B, Navarro-Vicente I, Lloret-Madrid P, Barragan E, Gil JV, Rodenas-Rovira M, Megias-Vericat JE, Labrador J, Peris-Ribera JE, Poveda-Andres JL, Montesinos P. Validation of pharmacokinetic model for quizartinib quantified by UPLC-MS/MS in patients with FLT3-ITD negative newly diagnosed acute myeloid leukemia. Eur J Clin Pharmacol. 2025 Aug 30. doi: 10.1007/s00228-025-03909-4. Online ahead of print. PubMed PMID: 40884550.
AÑO: 2025; IF: 2.4
|
|
Iniesta-Navalón C., Saorín M.R., Neira-Torrecillas J.M., Rentero-Redondo L., Garcia-Masegosa I., Gil-Almela J., Urbieta-Sanz E. External Evaluation of Population Pharmacokinetic Models of Ustekinumab in Patients with Inflammatory Bowel Disease. Therapeutic Drug Monitoring. 2025. 10.1097/FTD.0000000000001329
AÑO: 2025; IF: 2.8
|